COTELLIC (cobimetinib fumarate)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+2
GENENTECH
Drug class
Antineoplastic - MEK1 and MEK2 Kinase Inhibitors
Antineoplastic MEK1 and MEK2 kinase inhibitors are a class of targeted antineoplastic agents that selectively block the dual-specificity kinases mitogen-activated protein kinase kinase 1 and 2. Read more about Antineoplastic - MEK1 and MEK2 Kinase Inhibitors
9 drugs in this class 8 manufacturers
Drugs in Antineoplastic - MEK1 and MEK2 Kinase Inhibitors
MEKINIST (trametinib dimethyl sulfoxide)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+5
Novartis Pharmaceuticals
KOSELUGO (selumetinib sulfate)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMAS
AstraZeneca Pharmaceuticals
MEKTOVI (binimetinib)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+2
ARRAY/PFIZER
KOSELUGO (selumetinib sulfate)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMAS
AstraZeneca Pharmaceuticals
GOMEKLI (mirdametinib)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMAS
SPRINGWORKS THE
AVMAPKI (avutometinib potassium)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · LOW-GRADE SEROUS OVARIAN CANCER WITH KRAS MUTATION
VERASTEM, INC.
AVMAPKI-FAKZYNJA (avutometinib potassium/defactinib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · LOW-GRADE SEROUS OVARIAN CANCER WITH KRAS MUTATION
VERASTEM, INC.
MEKINIST (trametinib dimethyl sulfoxide)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS · MALIGNANT MELANOMA WITH BRAF V600E MUTATION ·+5
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - MEK1 and MEK2 Kinase Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic MEK1 and MEK2 kinase inhibitors are a class of targeted antineoplastic agents that selectively block the dual-specificity kinases mitogen-activated protein kinase kinase 1 and 2.
By suppressing MEK1/2 catalytic activity, these drugs interrupt the downstream phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) within the hyperactivated RAS-RAF-MEK-ERK signaling pathway, ultimately arresting cellular proliferation and inducing apoptosis in malignant cells.
They are clinically indicated—frequently in combination with BRAF inhibitors—for the treatment of malignancies harboring specific pathway alterations, most notably BRAF-mutant advanced melanoma, BRAF-mutant non-small cell lung cancer, and anaplastic thyroid carcinoma, as well as neurofibromatosis type 1-associated inoperable plexiform neurofibromas.
-
case.edu
Antineoplastic MEK1 and MEK2 kinase inhibitors are a class of targeted antineoplastic agents that selectively block the dual-specificity kinases mitogen-activated protein kinase kinase 1 and 2
-
wellfleetrx.com
Antineoplastic MEK1 and MEK2 kinase inhibitors are a class of targeted antineoplastic agents that selectively block the dual-specificity kinases mitogen-activated protein kinase kinase 1 and 2
-
patsnap.com
Antineoplastic MEK1 and MEK2 kinase inhibitors are a class of targeted antineoplastic agents that selectively block the dual-specificity kinases mitogen-activated protein kinase kinase 1 and 2 By suppressing MEK1/2 catalytic activity, these drugs interrupt the downstream phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) within the hyperactivated RAS-RAF-MEK-ERK signaling pathway, ultimately arresting cellular proliferation and inducing apoptosis in malignant cells
-
nih.gov
By suppressing MEK1/2 catalytic activity, these drugs interrupt the downstream phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) within the hyperactivated RAS-RAF-MEK-ERK signaling pathway, ultimately arresting cellular proliferation and inducing apoptosis in malignant cells
-
nih.gov
By suppressing MEK1/2 catalytic activity, these drugs interrupt the downstream phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) within the hyperactivated RAS-RAF-MEK-ERK signaling pathway, ultimately arresting cellular proliferation and inducing apoptosis in malignant cells
-
nih.gov
They are clinically indicated—frequently in combination with BRAF inhibitors—for the treatment of malignancies harboring specific pathway alterations, most notably BRAF-mutant advanced melanoma, BRAF-mutant non-small cell lung cancer, and anaplastic thyroid carcinoma, as well as neurofibromatosis type 1-associated inoperable plexiform neurofibromas
-
bocsci.com
They are clinically indicated—frequently in combination with BRAF inhibitors—for the treatment of malignancies harboring specific pathway alterations, most notably BRAF-mutant advanced melanoma, BRAF-mutant non-small cell lung cancer, and anaplastic thyroid carcinoma, as well as neurofibromatosis type 1-associated inoperable plexiform neurofibromas
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.